FDA Authorizes First Digital Therapeutic for Migraine
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of episodic migraine in adults, its development company announced in a statement. The mobile smartphone app uses biological, psychologic, and behavioral approaches to target pain processing and includes such tools
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of episodic migraine in adults, its development company announced in a statement. The mobile smartphone app uses biological, psychologic, and behavioral approaches to target pain processing and includes such tools …
Read More
About Author
